CJC-1295 + Ipamorelin Blend

What is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is a two-component research peptide blend that pairs CJC-1295 No DAC (Modified GRF 1-29), a tetrasubstituted 29-amino-acid GHRH analogue, with ipamorelin, a selective pentapeptide ghrelin receptor agonist. The two peptides are co-lyophilised in equal amounts in a single vial: 5mg + 5mg in the 10mg vial and 10mg + 10mg in the 20mg vial.

The rationale for co-investigation is that the two compounds act on different receptors. CJC-1295 No DAC stimulates the GHRH receptor to increase GH synthesis and release, while ipamorelin activates the ghrelin receptor (GHSR-1a) and suppresses somatostatin. Published preclinical research reports that combining a GHRH analogue with a ghrelin receptor agonist produces a greater GH response than either compound alone.

GenoPept supplies the CJC-1295 + Ipamorelin blend in the UK as a lyophilised research product in 10mg and 20mg vials. Each batch is verified by independent HPLC and LC-MS testing and is supplied strictly for laboratory research.

CJC-1295 + Ipamorelin research applications

Two-receptor synergy studies

The blend is used in pituitary cell and animal models to study the additive GH response when GHRH and ghrelin receptor pathways are activated together.

GH pulsatility research

Because both components are short-acting, CJC-1295 + Ipamorelin produces a defined GH pulse, useful for studies of pulse amplitude, frequency and IGF-1 response.

Somatostatin tone

Researchers use the combination to investigate how ghrelin receptor activation reduces somatostatin inhibition and thereby amplifies GHRH signalling.

Selective secretagogue profiling

Ipamorelin’s selectivity allows GH-related outcomes to be studied without the cortisol and prolactin confounders seen with GHRP-2 or GHRP-6.

Formulation and co-lyophilisation

The blend is also a model for studying compatibility, stability and analytical separation of two peptides in a single lyophilised formulation.

Mechanism of action (preclinical)

CJC-1295 No DAC binds the Gs-coupled GHRH receptor on pituitary somatotrophs, raising cAMP and driving GH gene transcription and release. Its four amino acid substitutions resist DPP-4 cleavage, giving a half-life of around 30 minutes in preclinical models.

Ipamorelin binds the Gq-coupled ghrelin receptor GHSR-1a, signalling through phospholipase C and calcium to trigger GH exocytosis, and acts in the hypothalamus to increase GHRH output and reduce somatostatin. Together, the two pathways converge on the somatotroph, which is why published research describes the combination as synergistic rather than merely additive.

CJC-1295 + Ipamorelin product specifications

Available sizes

• 10mg (5mg + 5mg) vial
• 20mg (10mg + 10mg) vial

Laboratories running larger studies can order bulk boxes of 10 vials, which save 20-50% against single-vial pricing; see the bulk and wholesale page. Orders over £200 ship free by tracked Royal Mail Special Delivery within the UK.

Reconstitution, handling and storage (laboratory)

CJC-1295 + Ipamorelin is supplied as a lyophilised powder that is stable for long-term storage at -20 °C. Unopened vials may be kept at 2-8 °C for short periods, protected from light. Allow a vial to reach room temperature before opening to avoid condensation on the powder.

For reconstitution, add bacteriostatic water or a sterile diluent slowly down the inside wall of the vial, then swirl gently until the powder dissolves. Never shake a peptide vial, because mechanical stress can damage the molecule and reduce measured purity.

After reconstitution, keep the solution at 2-8 °C and use it within the period stated in your laboratory protocol. Full guidance is available in our articles on how to reconstitute research peptides and how to store research peptides.

Quality assurance and Certificate of Analysis

Every batch of CJC-1295 + Ipamorelin sold by GenoPept is tested by an independent ISO/IEC 17025 laboratory (Puralytix). HPLC confirms purity of 99% or higher and LC-MS confirms molecular identity, so the compound in the vial matches the label.

Each product page carries a “View Certificate of Analysis” button, and the complete library is published at genopept.co.uk/coa-certificates. Vials are batch-identified with lot number and expiry date, and our guide to what a Certificate of Analysis shows explains how to read the report.

Related research compounds

• CJC-1295 No DAC (Modified GRF 1-29): the GHRH component supplied on its own for single-pathway controls.
• Ipamorelin: the ghrelin receptor component supplied on its own.
• CJC-1295 with DAC: a long-acting GHRH analogue for studies of sustained rather than pulsatile signalling.
• GHRP-2 (Pralmorelin): a less selective ghrelin receptor agonist for comparative synergy work.

CJC-1295 + Ipamorelin frequently asked questions

What is the CJC-1295 + Ipamorelin blend used for in research?

The CJC-1295 + Ipamorelin blend is used in laboratory research to study the combined activation of the GHRH receptor and the ghrelin receptor. Applications include synergy studies of GH release in pituitary cell and animal models, GH pulsatility and IGF-1 research, investigation of somatostatin tone, and formulation studies of co-lyophilised peptides. Supplied strictly for in-vitro research.

How is the blend supplied and what is in each vial?

GenoPept supplies CJC-1295 + Ipamorelin as a co-lyophilised powder in sealed, sterile glass vials. The 10mg vial contains 5mg CJC-1295 No DAC and 5mg ipamorelin; the 20mg vial contains 10mg of each. Every batch is tested by an independent ISO/IEC 17025 laboratory, with HPLC confirming purity of 99% or higher and LC-MS confirming the identity of both components.

How should CJC-1295 + Ipamorelin be stored?

Store unopened vials at -20 °C for long-term stability, or at 2-8 °C for short periods, protected from light. After reconstitution with bacteriostatic water, keep the solution refrigerated at 2-8 °C and use it within the period stated in your laboratory protocol. Add diluent gently down the vial wall and swirl to dissolve both components; never shake.

Is CJC-1295 + Ipamorelin for human use?

No. The CJC-1295 + Ipamorelin blend from GenoPept is supplied for in-vitro laboratory research only. It is not a medicine, is not for human or veterinary use, and is not intended for diagnostic or therapeutic purposes. GenoPept does not provide dosing, cycle or administration information, and purchasers must confirm they are buying for legitimate research in the UK.

Does the blend contain CJC-1295 with DAC or without DAC?

GenoPept’s blend uses CJC-1295 No DAC, also called Modified GRF (1-29). This short-acting form is chosen because its 30-minute half-life matches the short action of ipamorelin, producing a single defined GH pulse in preclinical models. CJC-1295 with DAC binds albumin and acts for days, which would change the pulse profile; it is available separately for sustained-signalling studies.

Research use only. This product is supplied for in-vitro laboratory research only. It is not for human or veterinary use, not a medicine, and not for diagnostic or therapeutic use. See our research use only policy and UK legal guide.